ESMO Gastrointestinal Oncology最新文献

Advances in anal cancer treatment: current standards, the role of immunotherapy and emerging strategies 肛门癌治疗的进展：目前的标准，免疫治疗的作用和新策略

IF 1.7

ESMO Gastrointestinal Oncology Pub Date : 2026-07-01 Epub Date: 2025-05-29 DOI: 10.1016/j.esmogo.2025.100180

P. Ntellas, V.K. Morris, S. Rao

引用次数: 0

Surgery in squamous cell carcinoma of the anus 肛门鳞状细胞癌的手术治疗

IF 1.7

ESMO Gastrointestinal Oncology Pub Date : 2026-07-01 Epub Date: 2025-10-31 DOI: 10.1016/j.esmogo.2025.100258

A.G. Renehan, P.J. Nilsson

引用次数: 0

Management of oligometastatic anal cancer—a literature review and a proposed treatment algorithm 少转移性肛门癌的治疗：文献回顾及建议的治疗算法

IF 1.7

ESMO Gastrointestinal Oncology Pub Date : 2026-07-01 Epub Date: 2025-07-22 DOI: 10.1016/j.esmogo.2025.100209

A. Johnsson, K.L. Wind, M.P. Nilsson

{"title":"Management of oligometastatic anal cancer—a literature review and a proposed treatment algorithm","authors":"A. Johnsson, K.L. Wind, M.P. Nilsson","doi":"10.1016/j.esmogo.2025.100209","DOIUrl":"10.1016/j.esmogo.2025.100209","url":null,"abstract":"<div><div>Oligometastatic squamous-cell carcinoma of the anus (omSCCA) is a very rare condition. The literature is sparse, and treatment guidelines are lacking. The aim of the present work was to carry out a literature review and to propose an algorithm for intensified treatment of patients with omSCCA. A PubMed search was carried out, which resulted in 15 relevant publications that included any type of definitive metastasis-directed therapy of mSCCA. All of the studies were retrospective. The local treatments were mostly surgical resections of liver metastases, but also radiofrequency ablation and radiotherapy were used, for metastases located in the liver, lungs, or other organs. The reported median overall survival across the studies ranged from 22 to 53 months. Three of the studies described extended-field chemoradiation of para-aortic lymph node metastases (M1 disease), suggesting long-term survival in up to half of the patients. Taken together, these results indicate that a subset of patients with omSCCA may benefit from a multimodal approach, including definitive metastasis-directed therapy given with curative intent. Based on the literature review and clinical experience, we propose a treatment algorithm, including metastasis-directed treatment as well as chemoradiation and induction chemotherapy. The choice of treatment and sequencing depends on the location and extent of the metastases and whether the metastases are synchronous or metachronous. In the absence of strong evidence, the proposed algorithm should be regarded as a starting point for discussions rather than detailed guidelines. Further studies and international collaborations are needed to optimize the treatment of omSCCA.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"13 ","pages":"Article 100209"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148582742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neoadjuvant and adjuvant chemotherapy in anal cancer – is there a role in the future? 新辅助和辅助化疗在肛管癌中的应用前景如何？

IF 1.7

ESMO Gastrointestinal Oncology Pub Date : 2026-07-01 Epub Date: 2025-08-27 DOI: 10.1016/j.esmogo.2025.100219

V. Vendrely, S. Kim, R. Glynne-Jones

引用次数: 0

Biological features of squamous cell carcinoma of the anus—a deep dive review 肛门鳞状细胞癌的生物学特征——综述

IF 1.7

ESMO Gastrointestinal Oncology Pub Date : 2026-07-01 Epub Date: 2025-04-03 DOI: 10.1016/j.esmogo.2025.100157

R.J. Samuel, N. Winder, M. Busk, K. Lycke Wind, G. Guerra, A.G. Heriot, D.C. Gilbert, A. Macdonald, K.-L. Garm Spindler

{"title":"Biological features of squamous cell carcinoma of the anus—a deep dive review","authors":"R.J. Samuel, N. Winder, M. Busk, K. Lycke Wind, G. Guerra, A.G. Heriot, D.C. Gilbert, A. Macdonald, K.-L. Garm Spindler","doi":"10.1016/j.esmogo.2025.100157","DOIUrl":"10.1016/j.esmogo.2025.100157","url":null,"abstract":"<div><div>Squamous cell carcinoma of the anus (SCCA) is a human papillomavirus (HPV)-associated cancer with an increasing incidence. Localized disease is treated curatively with chemoradiotherapy (CRT) but has substantial toxicities and impact on quality of life. Despite increasing research over the past decade, much of our biological understanding of SCCA is extrapolated from other HPV-associated cancers. Recently launched initiatives aim to connect clinicians and basic researchers working in SCCA to foster collaboration and knowledge sharing and facilitate access to SCCA materials. To improve outcomes for SCCA patients, a better understanding of SCCA-specific biology is required. This review will discuss areas of SCCA biology that are important to developing targets for drug development and biomarker-based individualized precision treatment. It will discuss the current understanding of radiosensitivity, differences in HPV-positive versus HPV-negative disease, hypoxia, immune environment, molecular characteristics, circulating tumor HPV-DNA, and the microbiome. It will detail when this understanding has been extrapolated from other HPV-associated cancers. Finally, it will discuss our current and upcoming preclinical biological models and discuss future models needed to further our understanding of SCCA biology.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"13 ","pages":"Article 100157"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148571666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence and burden of anal cancer—time to fight the growing disparities 肛门癌的发病率和负担时间差距越来越大

IF 1.7

ESMO Gastrointestinal Oncology Pub Date : 2026-07-01 Epub Date: 2025-02-24 DOI: 10.1016/j.esmogo.2025.100147

E.S.L. Pedersen, D. Verschoor, E. Segelov

{"title":"Incidence and burden of anal cancer—time to fight the growing disparities","authors":"E.S.L. Pedersen, D. Verschoor, E. Segelov","doi":"10.1016/j.esmogo.2025.100147","DOIUrl":"10.1016/j.esmogo.2025.100147","url":null,"abstract":"<div><div>Anal cancer (AC) is rare, but its incidence is increasing, although at different rates across countries and population groups. The increase in AC incidence is primarily due to the increased prevalence of human papillomavirus (HPV), which causes 90% of squamous-cell carcinoma (SCC), the most common AC histology subtype. Understanding estimates of incidence across countries and risk groups is essential for estimating future disease burden and predicting cancer care resource allocation. In this review, we summarize the latest literature with an emphasis on global disparities and challenges in AC prevention. Globally in 2020, >30 000 people were diagnosed with anal SCC, with two-thirds of cases occurring in North America and Europe. AC incidence varies greatly between population groups; higher incidence is associated with older age, females, anal sexual intercourse, immunosuppression [particularly people living with human immunodeficiency virus (HIV) and solid organ transplant recipients], and prior HPV-related gynecologic (pre-)cancers. Primary prevention of AC relies on preventing HPV infection by vaccination and secondary prevention relies on screening and treatment of high-grade squamous intraepithelial lesions (HSILs). Globally, there are considerable disparities in AC. While its incidence is currently highest in high-income countries, it is expected to increase in low-income countries (LICs) in the future, due to higher HPV prevalence and lower HPV vaccine coverage. Continued effort is essential to gather data on prevalence and incidence, especially in LICs, to strengthen vaccination programs globally and to promote research networks around the world for better evidence on screening and treatment.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"13 ","pages":"Article 100147"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148582741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of anal cancer in older patients and patients with frailty 高龄及体弱多病患者肛门癌的治疗

IF 1.7

ESMO Gastrointestinal Oncology Pub Date : 2026-07-01 Epub Date: 2025-03-27 DOI: 10.1016/j.esmogo.2025.100155

A. Gilbert, S. Rostoft, V. Vendrely, R. Muirhead, J. Pearce, A. Lièvre, M.G. Guren

{"title":"Treatment of anal cancer in older patients and patients with frailty","authors":"A. Gilbert, S. Rostoft, V. Vendrely, R. Muirhead, J. Pearce, A. Lièvre, M.G. Guren","doi":"10.1016/j.esmogo.2025.100155","DOIUrl":"10.1016/j.esmogo.2025.100155","url":null,"abstract":"<div><div>The incidence and age of patients with anal cancer is increasing. With the changing demographics, there is an increasing need to develop harmonised treatment approaches for patients not fit for standard-of-care chemoradiotherapy (CRT). This paper reviews the literature on the treatment of non-metastatic anal cancer in older or frail patients. We then describe assessment and management of frailty in patients with anal cancer. We present results from an international survey of anal cancer clinicians (<em>n</em> = 45) to provide a snapshot of self-reported current practice of patients who are unsuitable for standard CRT. The results highlight the heterogeneous practice in this area, due to the lack of clinical trials focusing on older and frailer patients. Potential modification strategies are proposed for older, comorbid, unfit, and frail patients in the management of anal cancer based on the literature and the survey results of current practice. For patients unfit for CRT, this may involve modified chemotherapy or radiotherapy doses, and for patients with severe frailty, palliative radiotherapy regimens. Finally, we describe challenges, limitations, and considerations for future research in this area.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"13 ","pages":"Article 100155"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148571662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patients’ perspective in anal cancer 肛门癌患者的观点

IF 1.7

ESMO Gastrointestinal Oncology Pub Date : 2026-07-01 Epub Date: 2025-07-11 DOI: 10.1016/j.esmogo.2025.100203

S. Manfrida, L. Dinapoli, V. De Luca, G. Chiloiro, A. Romano, D.P.R. Chieffo, E. Segelov, P. Franco, M.A. Gambacorta

{"title":"Patients’ perspective in anal cancer","authors":"S. Manfrida, L. Dinapoli, V. De Luca, G. Chiloiro, A. Romano, D.P.R. Chieffo, E. Segelov, P. Franco, M.A. Gambacorta","doi":"10.1016/j.esmogo.2025.100203","DOIUrl":"10.1016/j.esmogo.2025.100203","url":null,"abstract":"<div><div>The high chance for an anal cancer patient to be a long-term survivor stresses the importance of quality of life (QoL) after treatment. Radiation therapy targeting the anal canal can impair anorectal, urinary, and sexual functions. Patients’ viewpoints regarding their overall care experiences are aimed at improving information for both patients and healthcare providers to address their unmet needs. This review examines patient perspectives from diagnosis through survivorship, encompassing physical and psychological impacts, side-effect management, and transitioning to survivorship. Two cross-cutting aspects are the psychological and socio-financial aspects. Patient-reported outcome measures (PROMs) offer insights into concerns and guide interventions, yet long-term QoL studies are limited. Qualitative analysis complements PROMs, offering deeper insights for tailored counseling. Educating patients and caregivers on managing acute side-effects is vital, with early identification of at-risk patients being crucial. Late complications are common and severe, often leaving patients feeling unsupported. Supportive care also plays a crucial role in managing treatment-related side-effects and optimizing recovery from skin care for radiation dermatitis, pain management, pelvic floor physical therapy for sexual dysfunction during and after treatment, use of vaginal dilators during radiation treatment, topical vaginal hormone therapy, and counseling for sexual dysfunction. With the goal of providing increasing integration of services for patients with anal malignancies, patient organizations (such as the Anal Cancer Foundation) have sprung up to offer support, educational initiatives, and resources to improve patient outcomes and QoL.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"13 ","pages":"Article 100203"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148571674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapy for squamous-cell carcinoma of the anus in HIV-positive patients hiv阳性患者肛门鳞状细胞癌的治疗

IF 1.7

ESMO Gastrointestinal Oncology Pub Date : 2026-07-01 Epub Date: 2025-03-18 DOI: 10.1016/j.esmogo.2025.100156

C. Evin, M.P.G. Camandaroba, R.P. Riechelmann, F. Huguet

{"title":"Therapy for squamous-cell carcinoma of the anus in HIV-positive patients","authors":"C. Evin, M.P.G. Camandaroba, R.P. Riechelmann, F. Huguet","doi":"10.1016/j.esmogo.2025.100156","DOIUrl":"10.1016/j.esmogo.2025.100156","url":null,"abstract":"<div><h3>Introduction</h3><div>Squamous-cell carcinoma of the anus (SCCA) is one of the most common cancers arising in people living with human immunodeficiency virus (HIV). However, these patients have been underrepresented in clinical trials of SCCA-directed therapies, which limits treatment recommendations. We carried out an extensive literature review of treatment outcomes of HIV-positive patients with SCCA.</div></div><div><h3>Methods</h3><div>We sought the Medline® database to identify studies, meta-analyses, and systematic reviews on the efficacy and toxicity of treatments for patients with SCCA and HIV.</div></div><div><h3>Results</h3><div>Thirty-seven studies were included. HIV-positive patients with SCCA were younger and predominantly male. The overall complete response rate after chemoradiotherapy is ∼80%, but locoregional recurrence and survival seems worse. While toxicity after chemoradiotherapy appears to be worse in HIV-positive patients in the first published series, recent analysis of HIV-positive patients treated with intensity-modulated radiotherapy did not show a difference in tolerance.</div></div><div><h3>Conclusions</h3><div>The evidence to guide treatments for HIV-positive patients with SCCA is weak. Overall, patients with preserved immunity should not be spared of full chemoradiation in localized disease. Recent clinical trials of immune checkpoint inhibitors are currently enrolling HIV-positive patients and will help define the role of immunotherapy for these patients.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"13 ","pages":"Article 100156"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148571665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rewriting the future of anal cancer care: From disparities to data-driven decisions 改写肛门癌护理的未来：从差异到数据驱动的决策

IF 1.7

ESMO Gastrointestinal Oncology Pub Date : 2026-07-01 Epub Date: 2026-07-20 DOI: 10.1016/j.esmogo.2026.100373

D. Arnold, K.-L.G. Spindler

引用次数: 0